Human herpesvirus 6 (HHV-6) causes significant complications after hematopoietic stem cell transplantation (SCT) including skin rash, encephalitis, pneumonia, and bone marrow suppression.
1,2 HHV-6 is classified into two variants, A (HHV-6A) and B (HHV-6B). The two variants are thought to have different epidemiologies. Most symptomatic HHV-6 infections after SCT are caused by HHV-6B. [3] [4] [5] Although HHV-6A has occasionally been isolated after SCT, 6, 7 the pathogenicity of HHV-6A remains largely uncertain. Here, we describe the first case of HHV-6A infection after umbilical cord blood transplantation (CBT).
In April 1999, a 49-year-old woman with overt leukemia from myelodysplastic syndrome underwent CBT from an HLA-one-antigen-mismatched donor. The grafts contained 2.1 Â 10 7 /kg total nucleated cells and 0.2 Â 10 5 /kg CD34-positive cells. The conditioning regimen included 12 Gy total body irradiation, 120 mg cyclophosphamide, and 12 g/m 2 cytarabine with the concomitant administration of recombinant human granulocyte colony-stimulating factor. 8 Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin and methotrexate. She received 1000 mg/day acyclovir orally from day À3 to day 35 to prevent herpes simplex virus reactivation. From day 12 to 17 after CBT, she developed fever higher than 38.01C with the maximum temperature of 39.61C on day 16 (Figure 1 ). On day 13, an erythematous skin rash occurred in the forearms and hands. On day 16, the serum aspartate aminotransferase (ALT) and alanine aminotransferase (AST) levels were mildly elevated to 36 and 56 IU/l, respectively (normal, within 30 IU/l). The maximum levels of AST and ALT were 36 IU/l on day 16 and 85 IU/l on day 18, respectively. No jaundice, body weight gain, edema, or pulmonary symptoms were observed. These symptoms resolved spontaneously without additional antiviral therapy. On day 26, myeloid engraftment with an absolute neutrophil count of more than 500/ml was achieved. No acute or chronic GVHD were observed. She did not developed cytomegalovirus infection. No bacterial or fungal infections were documented. By a real-time quantitative polymerase chain reaction (PCR) method, 9 the presence of HHV-6A DNA in serum was retrospectively examined. HHV-6A DNA was detected in serum samples on days 14, 21, and 28 after CBT with levels of 1 Â 10 3 , 6 Â 10 3 , and 2 Â 10 2 copies/ml, respectively (lower limit of detection, 2 Â 10 2 copies/ml). However, HHV-6A DNA was not detected in serum samples on days 7 or 35 after CBT. HHV-6B DNA was not detected in any serum samples obtained from day 7-35 after CBT. After a post-CBT follow-up of 72 months, she is currently alive without disease progression.
We have previously examined the incidences of HHV-6B infection in adults after CBT and bone marrow transplantation (BMT) by a real-time quantitative PCR method on www.nature.com/bmt serum samples. 10 HHV-6B DNA was more frequently detected in serum samples at weeks 2 or 3 after CBT than BMT (20 of 23 patients, 87% vs 4 of 21 patients, 19%, Po0.0001). By using the same methodology, we studied the incidence of HHV-6A infection in 50 adults after CBT. In one patient (2%), as described above, HHV-6A DNA was detected in serum samples on days 14, 21, and 28 after CBT. In the remaining 49 patients, HHV-6A DNA was not detected. The presence of HHV-6 DNA in peripheral blood or other samples does not necessarily indicate clinical disease. 1 In addition, further examination for other pathogenic viruses were not undertaken in our patient. However, previous studies have shown that detection of HHV-6 DNA in serum or plasma is a useful marker of active infection. 2, 5, 6 Thus, fever, skin rash, and liver dysfunction in our patient were considered to be associated with HHV-6A infection. This is the first report studying the incidence and the clinical features of HHV-6A infection in the early period after CBT.
The majority of HHV-6 infections after SCT are caused by HHV-6B. [3] [4] [5] However, Secchiero et al 6 examined infections by HHV-6A and HHV-6B differentially by a PCR method, on serum samples after BMT. In three of 13 patients (23%), HHV-6A DNA was transiently detected during episodes of fever and pulmonary symptoms after BMT. In these three patients, HHV-6A DNA in serum was first detected on days À3, 88, and 123 after BMT. However, HHV-6B DNA was not detected in the 13 patients. The incidence of symptomatic HHV-6A infections in the study seemed to be higher than in other studies. In Japanese adults, most HHV-6 infections within 4 weeks after CBT are caused by HHV-6B. Despite the relatively low incidence of HHV-6A infection after CBT, the pathogenesis of HHV-6A needs to be examined further.
